Cargando…

Multi-Institutional Patterns of Use of Tumor-Treating Fields for Patients with Malignant Pleural Mesothelioma

(1) Background: The objective of this analysis was to evaluate the device usage rates and patterns of use regarding Tumor-Treating Fields (TTFields) for patients with malignant pleural mesothelioma (MPM) throughout the US. (2) Methods: We evaluated de-identified data from 33 patients with MPM enroll...

Descripción completa

Detalles Bibliográficos
Autores principales: Kutuk, Tugce, Walker, Joshua M., Ballo, Matthew T., Cameron, Robert B., Alvarez, Jean Bustamante, Chawla, Sheema, Luk, Eric, Behl, Deepti, Dal Pra, Alan, Morganstein, Neil, Refaat, Tamer, Sheybani, Arshin, Squillante, Christian, Zhang, Jun, Kotecha, Rupesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297418/
https://www.ncbi.nlm.nih.gov/pubmed/37366877
http://dx.doi.org/10.3390/curroncol30060394
_version_ 1785063879020118016
author Kutuk, Tugce
Walker, Joshua M.
Ballo, Matthew T.
Cameron, Robert B.
Alvarez, Jean Bustamante
Chawla, Sheema
Luk, Eric
Behl, Deepti
Dal Pra, Alan
Morganstein, Neil
Refaat, Tamer
Sheybani, Arshin
Squillante, Christian
Zhang, Jun
Kotecha, Rupesh
author_facet Kutuk, Tugce
Walker, Joshua M.
Ballo, Matthew T.
Cameron, Robert B.
Alvarez, Jean Bustamante
Chawla, Sheema
Luk, Eric
Behl, Deepti
Dal Pra, Alan
Morganstein, Neil
Refaat, Tamer
Sheybani, Arshin
Squillante, Christian
Zhang, Jun
Kotecha, Rupesh
author_sort Kutuk, Tugce
collection PubMed
description (1) Background: The objective of this analysis was to evaluate the device usage rates and patterns of use regarding Tumor-Treating Fields (TTFields) for patients with malignant pleural mesothelioma (MPM) throughout the US. (2) Methods: We evaluated de-identified data from 33 patients with MPM enrolled in FDA-required HDE protocols at 14 institutions across the US from September 2019 to March 2022. (3) Results: The median number of total TTFields usage days was 72 (range: 6–649 days), and the total treatment duration was 160 months for all patients. A low usage rate (defined as less than 6 h per day, 25%) was observed in 34 (21.2%) months. The median TTFields usage in the first 3 months was 12 h per day (range: 1.9–21.6 h), representing 50% (range: 8–90%) of the potential daily duration. The median TTFields usage after 3 months decreased to 9.1 h per day (range: 3.1–17 h), representing 38% (range: 13–71%) of the daily duration, and was lower than usage in the first 3 months (p = 0.01). (4) Conclusions: This study represents the first multicenter analysis of real-world TTFields usage based on usage patterns for MPM patients in clinical practice. The real-world usage level was lower than the suggested daily usage. Further initiatives and guidelines should be developed to evaluate the impact of this finding on tumor control.
format Online
Article
Text
id pubmed-10297418
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102974182023-06-28 Multi-Institutional Patterns of Use of Tumor-Treating Fields for Patients with Malignant Pleural Mesothelioma Kutuk, Tugce Walker, Joshua M. Ballo, Matthew T. Cameron, Robert B. Alvarez, Jean Bustamante Chawla, Sheema Luk, Eric Behl, Deepti Dal Pra, Alan Morganstein, Neil Refaat, Tamer Sheybani, Arshin Squillante, Christian Zhang, Jun Kotecha, Rupesh Curr Oncol Communication (1) Background: The objective of this analysis was to evaluate the device usage rates and patterns of use regarding Tumor-Treating Fields (TTFields) for patients with malignant pleural mesothelioma (MPM) throughout the US. (2) Methods: We evaluated de-identified data from 33 patients with MPM enrolled in FDA-required HDE protocols at 14 institutions across the US from September 2019 to March 2022. (3) Results: The median number of total TTFields usage days was 72 (range: 6–649 days), and the total treatment duration was 160 months for all patients. A low usage rate (defined as less than 6 h per day, 25%) was observed in 34 (21.2%) months. The median TTFields usage in the first 3 months was 12 h per day (range: 1.9–21.6 h), representing 50% (range: 8–90%) of the potential daily duration. The median TTFields usage after 3 months decreased to 9.1 h per day (range: 3.1–17 h), representing 38% (range: 13–71%) of the daily duration, and was lower than usage in the first 3 months (p = 0.01). (4) Conclusions: This study represents the first multicenter analysis of real-world TTFields usage based on usage patterns for MPM patients in clinical practice. The real-world usage level was lower than the suggested daily usage. Further initiatives and guidelines should be developed to evaluate the impact of this finding on tumor control. MDPI 2023-05-23 /pmc/articles/PMC10297418/ /pubmed/37366877 http://dx.doi.org/10.3390/curroncol30060394 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Kutuk, Tugce
Walker, Joshua M.
Ballo, Matthew T.
Cameron, Robert B.
Alvarez, Jean Bustamante
Chawla, Sheema
Luk, Eric
Behl, Deepti
Dal Pra, Alan
Morganstein, Neil
Refaat, Tamer
Sheybani, Arshin
Squillante, Christian
Zhang, Jun
Kotecha, Rupesh
Multi-Institutional Patterns of Use of Tumor-Treating Fields for Patients with Malignant Pleural Mesothelioma
title Multi-Institutional Patterns of Use of Tumor-Treating Fields for Patients with Malignant Pleural Mesothelioma
title_full Multi-Institutional Patterns of Use of Tumor-Treating Fields for Patients with Malignant Pleural Mesothelioma
title_fullStr Multi-Institutional Patterns of Use of Tumor-Treating Fields for Patients with Malignant Pleural Mesothelioma
title_full_unstemmed Multi-Institutional Patterns of Use of Tumor-Treating Fields for Patients with Malignant Pleural Mesothelioma
title_short Multi-Institutional Patterns of Use of Tumor-Treating Fields for Patients with Malignant Pleural Mesothelioma
title_sort multi-institutional patterns of use of tumor-treating fields for patients with malignant pleural mesothelioma
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297418/
https://www.ncbi.nlm.nih.gov/pubmed/37366877
http://dx.doi.org/10.3390/curroncol30060394
work_keys_str_mv AT kutuktugce multiinstitutionalpatternsofuseoftumortreatingfieldsforpatientswithmalignantpleuralmesothelioma
AT walkerjoshuam multiinstitutionalpatternsofuseoftumortreatingfieldsforpatientswithmalignantpleuralmesothelioma
AT ballomatthewt multiinstitutionalpatternsofuseoftumortreatingfieldsforpatientswithmalignantpleuralmesothelioma
AT cameronrobertb multiinstitutionalpatternsofuseoftumortreatingfieldsforpatientswithmalignantpleuralmesothelioma
AT alvarezjeanbustamante multiinstitutionalpatternsofuseoftumortreatingfieldsforpatientswithmalignantpleuralmesothelioma
AT chawlasheema multiinstitutionalpatternsofuseoftumortreatingfieldsforpatientswithmalignantpleuralmesothelioma
AT lukeric multiinstitutionalpatternsofuseoftumortreatingfieldsforpatientswithmalignantpleuralmesothelioma
AT behldeepti multiinstitutionalpatternsofuseoftumortreatingfieldsforpatientswithmalignantpleuralmesothelioma
AT dalpraalan multiinstitutionalpatternsofuseoftumortreatingfieldsforpatientswithmalignantpleuralmesothelioma
AT morgansteinneil multiinstitutionalpatternsofuseoftumortreatingfieldsforpatientswithmalignantpleuralmesothelioma
AT refaattamer multiinstitutionalpatternsofuseoftumortreatingfieldsforpatientswithmalignantpleuralmesothelioma
AT sheybaniarshin multiinstitutionalpatternsofuseoftumortreatingfieldsforpatientswithmalignantpleuralmesothelioma
AT squillantechristian multiinstitutionalpatternsofuseoftumortreatingfieldsforpatientswithmalignantpleuralmesothelioma
AT zhangjun multiinstitutionalpatternsofuseoftumortreatingfieldsforpatientswithmalignantpleuralmesothelioma
AT kotecharupesh multiinstitutionalpatternsofuseoftumortreatingfieldsforpatientswithmalignantpleuralmesothelioma